Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.

NCT06905288 · clinicaltrials.gov ↗

RECRUITING

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Ankylosing Spondylitis

Interventions

DRUG: Secukinumab

Sponsor

Novartis Pharmaceuticals